Dianthus Therapeutics, Inc. (DNTH)Healthcare | Biotechnology | New York, United States | NasdaqCM
98.64 USD
+1.04
(1.066%)
⇧
(July 13, 2026, 4 p.m.
EDT)
After hours: 98.64 |
Hot Take ↕ | July 11, 2026, 6:34 a.m. EDT
The immediate outlook is bullish, driven by a technical breakout above key moving averages and a surge in call activity surrounding the Phase 3 trial initiation. The stock has rallied sharply over the last two weeks, trading near its fifty-two-week high, which validates the short-term momentum thesis. However, the long-term picture is murky; revenue has contracted by sixty percent year-over-year, and the company is burning cash despite a fortress-like balance sheet. The massive cash reserve prevents bankruptcy, but it does not solve the core problem of shrinking sales. Investors are paying a premium for clinical success, but the fundamentals currently tell a story of decline. This is a speculative vehicle for near-term catalysts, not a stable investment for wealth preservation. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.044329 |
| MSTL | 0.049075 |
| AutoETS | 0.051828 |
| AutoARIMA | 0.053797 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 36% |
| H-stat | 3.67 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.219 |
| Excess Kurtosis | -0.14 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.114 |
| Revenue per Share | 0.032 |
| Market Cap | 5,392,276,992 |
| Forward P/E | -21.21 |
| Beta | 0.09 |
| Website | https://dianthustx.com |
As of July 11, 2026, 6:34 a.m. EDT: Implied volatility remains elevated across expiration cycles, signaling uncertainty. Near-term call volume exceeds put volume, with significant open interest concentrated in in-the-money strikes for July and August 2026, suggesting speculators are positioning for upside momentum following the Phase 3 trial launch. However, deep out-of-the-money put open interest in January 2027 indicates hedging against a potential downside event, creating a bifurcated sentiment where traders expect a rally but fear a sharp correction.
| Attribute | Value |
|---|---|
| 52 Week Change | 3.8726912 |
| Address1 | 7 Times Square |
| Address2 | 43rd Floor |
| All Time High | 336.0 |
| All Time Low | 5.12 |
| Ask | 121.83 |
| Ask Size | 2 |
| Audit Risk | 8 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 1,641,120 |
| Average Daily Volume3 Month | 937,493 |
| Average Volume | 937,493 |
| Average Volume10Days | 1,641,120 |
| Beta | 0.089 |
| Bid | 70.95 |
| Bid Size | 2 |
| Board Risk | 6 |
| Book Value | 22.009 |
| City | New York |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 98.64 |
| Current Ratio | 29.253 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 98.96 |
| Day Low | 93.85 |
| Debt To Equity | 0.114 |
| Display Name | Dianthus Therapeutics |
| Earnings Timestamp | 1,778,011,200 |
| Earnings Timestamp End | 1,778,011,200 |
| Earnings Timestamp Start | 1,778,011,200 |
| Ebitda | -191,172,992 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -22.401 |
| Enterprise To Revenue | 3,205.376 |
| Enterprise Value | 4,282,382,336 |
| Eps Current Year | -3.92667 |
| Eps Forward | -4.65111 |
| Eps Trailing Twelve Months | -4.23 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 87.7026 |
| Fifty Day Average Change | 10.937401 |
| Fifty Day Average Change Percent | 0.12471011 |
| Fifty Two Week Change Percent | 387.2691 |
| Fifty Two Week High | 102.33 |
| Fifty Two Week High Change | -3.6900024 |
| Fifty Two Week High Change Percent | -0.03605983 |
| Fifty Two Week Low | 18.08 |
| Fifty Two Week Low Change | 80.56 |
| Fifty Two Week Low Change Percent | 4.455752 |
| Fifty Two Week Range | 18.08 - 102.33 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,529,587,800,000 |
| Float Shares | 54,596,807 |
| Forward Eps | -4.65111 |
| Forward P E | -21.20784 |
| Free Cashflow | -71,029,624 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 92 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 1.0 |
| Gross Profits | 1,336,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00127 |
| Held Percent Institutions | 1.21174 |
| Implied Shares Outstanding | 54,666,233 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York. |
| Long Name | Dianthus Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 5,392,276,992 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_631649032 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -173,660,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 5,332,144,366 |
| Number Of Analyst Opinions | 12 |
| Open | 96.42 |
| Operating Cashflow | -130,286,000 |
| Operating Margins | -100.50324 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 929 999 4055 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 98.64 |
| Post Market Time | 1,783,981,120 |
| Previous Close | 97.6 |
| Price Eps Current Year | -25.120522 |
| Price Hint | 2 |
| Price To Book | 4.481803 |
| Price To Sales Trailing12 Months | 4,036.1355 |
| Profit Margins | 0.0 |
| Quick Ratio | 29.06 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | 1.04 |
| Regular Market Change Percent | 1.06557 |
| Regular Market Day High | 98.96 |
| Regular Market Day Low | 93.85 |
| Regular Market Day Range | 93.85 - 98.96 |
| Regular Market Open | 96.42 |
| Regular Market Previous Close | 97.6 |
| Regular Market Price | 98.64 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 537,120 |
| Return On Assets | -0.14987001 |
| Return On Equity | -0.22702 |
| Revenue Growth | -0.602 |
| Revenue Per Share | 0.032 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 54,666,233 |
| Shares Percent Shares Out | 0.1744 |
| Shares Short | 9,533,151 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 6,690,110 |
| Short Name | Dianthus Therapeutics, Inc. |
| Short Percent Of Float | 0.2007 |
| Short Ratio | 6.36 |
| Source Interval | 15 |
| State | NY |
| Symbol | DNTH |
| Target High Price | 200.0 |
| Target Low Price | 105.0 |
| Target Mean Price | 128.58333 |
| Target Median Price | 125.0 |
| Total Cash | 1,111,259,008 |
| Total Cash Per Share | 20.328 |
| Total Debt | 1,364,000 |
| Total Revenue | 1,336,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -4.23 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 61.6238 |
| Two Hundred Day Average Change | 37.0162 |
| Two Hundred Day Average Change Percent | 0.6006803 |
| Type Disp | Equity |
| Volume | 537,120 |
| Website | https://dianthustx.com |
| Zip | 10,036 |